UnitedHealth Q3 2026 Earnings: EPS $4.56 (+76%), Medical Care Ratio 88.4%

On October 13, 2026, UnitedHealth Group (NYSE: UNH) reported third-quarter results that read like a company climbing out of its own 2025 hole: revenues of $112.7 billion (essentially flat), earnings from operations of $6.6 billion (+52%), diluted EPS of $4.56 (+76%) and adjusted EPS of $4.69, then raised full-year guidance to at least $19.50 GAAP and at least $20.50 adjusted. The engine is the medical care ratio, down 150 basis points to 88.4% on medical costs that fell 3.7% against premiums that fell only 2.1% — the first quarter in two years where the cost line moved faster than the revenue line in the right direction. But $610 million of that improvement is favorable prior-period reserve development, membership shrank by 1.8 million year over year, and Optum Health's revenue fell 10% even as its earnings recovered. This is the quarter discipline beat growth, and the numbers say exactly which kind of discipline.

The Headline Numbers​

UnitedHealth's fiscal year is the calendar year; Q3 2026 ended September 30, 2026. Every figure below comes from the Form 8-K and its earnings release (Exhibit 99.1), which carries the full condensed income statement, balance sheet and cash flow statement. No 10-Q had been filed as of this writing, so the balance sheet below is the exhibit's condensed presentation.

Read the table top-down and the story is subtraction, not addition. Revenue fell $467 million, yet earnings from operations rose $2,248 million — because medical costs fell $2,976 million and operating costs fell $854 million. Premiums shrank 2.1% on membership losses, but medical costs shrank 3.7%, and that 160-basis-point gap between the two growth rates is the entire quarter: it flows straight through a cost base where every other line is comparatively small. Below the operating line there is little drama — interest eased, the South America held-for-sale loss was just $76 million, and the tax rate of 22.2% is unremarkable — so the +75% net income print is almost purely the medical-cost beat plus operating leverage running in reverse, on costs instead of sales.

The GAAP-to-adjusted bridge, straight from the release's reconciliation:

Note the direction of the adjustments: the divestiture and restructuring lines are subtracted, meaning the quarter's GAAP number was flattered by $222 million of net gains on businesses held for sale and asset sales, partly offset by losses on the remaining South American operations. The clean $0.41 of intangible amortization is the recurring add-back; everything else says reported earnings ran ahead of underlying earnings this quarter, not behind them.

Revenue Deep Dive: Two Businesses, Opposite Directions​

UnitedHealth is two companies stapled together — the UnitedHealthcare insurer and the Optum care-and-services platform — and they moved in opposite directions this quarter:

UnitedHealthcare (−0.9% revenue, +57% earnings) is the margin story in miniature. Revenues slipped $740 million, but earnings rose more than $1 billion — every dollar of it from the medical-cost line. Inside the segment, Employer & Individual grew 1.7% to $20,208 million while Medicare & Retirement fell 2.2% to $42,420 million and Community & State slipped 0.6% to $23,702 million. The mix matters because the release says the earnings gain came from "benefit changes and pricing discipline, combined with medical and operating cost management" — pricing language, not growth language. Membership tells the same story from the other side: 48.3 million served, down 1.8 million year over year, with seniors through Medicare Advantage contracting by 935,000 since year-end 2025. UnitedHealthcare is deliberately getting smaller and more profitable at the same time.

Optum Health (−9.9% revenue, earnings up 17-fold) is the quarter's strangest line. Revenue fell $2.5 billion "as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians" — the company is openly retreating from value-based markets where it cannot make the math work — yet earnings went from $41 million to $735 million on "strengthened operational discipline and medical cost management initiatives across its value-based care markets." Read that pair together: Optum Health shed its worst revenue and kept the margin. Consumers served held roughly flat at 92 million, so the exit is selective, not a collapse.

Optum Insight (+2.9% revenue, +39% earnings) is the quiet compounder. A 23.4% operating margin — up more than six points — on "enhanced product offerings and operational efficiencies," with the release pointing at AI-enabled tools for clinical documentation and payment accuracy. This is the only segment where the release uses anything close to product-ramp language, and even here it stops short of claiming outperformance: no theme from the demand side of the ledger appears anywhere in the release. For a company reporting a 52% operating-earnings beat, the absence of the words "demand," "growth momentum" or "strong bookings" anywhere in the commentary is itself the signal — management is selling execution, not a demand cycle.

Optum Rx (+0.6% revenue, +11% earnings) grew earnings on biosimilar adoption and operational improvements while adjusted scripts fell from 414 million to 393 million "due to membership declines within UnitedHealthcare and other customers." The pharmacy business is earning more per script on fewer scripts — pricing and mix, again, not volume.

The Margin Story: 150 Basis Points, Mechanically​

The managed-care P&L has exactly two ratios that matter, and both moved the right way. Here they are across five periods:

(Q2 2026 column: revenues $112.0 billion and earnings from operations $8.0 billion per the release's quarterly table, for a 7.1% operating margin and 4.9% net margin; the release does not disclose Q2 ratios.)

The 150-basis-point MCR improvement decomposes cleanly. Premiums fell 2.1% while medical costs fell 3.7% — Had medical costs merely matched the premium decline, the ratio would have been flat; the extra 1.6 points of cost decline is the improvement, worth roughly $1.4 billion pre-tax. Inside that, $610 million is "net favorable prior period reserve development related to 2026 dates of service" — about 70 basis points of the 150, and the part a skeptic discounts first, since reserve releases are management's estimate of yesterday's costs, not today's performance. The remaining ~80 basis points is the real thing: "medical cost management initiatives, benefit design changes and pricing discipline, as well as care delivery enhancements."

The release's pricing language deserves a ledger check, because "pricing discipline" in managed care usually means raising premiums per member while losing members — and the ledger confirms exactly that. Premium revenue fell only 2.1% while medical membership fell 3.6% (48.3 million vs 50.1 million), so premium per member rose roughly 1.5%. Price up, volume down, costs down more: that is the textbook execution of a pricing-discipline quarter, and Days Claims Payable holding flat at 47.0 (vs 46.2 a year ago) says the reserve position was not stretched to manufacture it. Days Sales Outstanding improving to 16.9 from 18.6 says collections helped too.

The operating cost ratio's 70-basis-point drop (12.8% vs 13.5%) is the smaller but arguably more durable win: operating costs fell $854 million in absolute dollars while the company says it is accelerating investment in "technology, processes and people." Costs down while investing up means the cuts came from real efficiency — "operational agentification" is the release's word — not from deferred spending.

The One Big Question: Is the Medical-Cost Crisis Over?​

Step back and Q3 2026 is the third data point in the most important sequence in managed care. In FY2024, UnitedHealth's medical care ratio was 85.5% and the company earned $14.4 billion attributable. In FY2025, the ratio blew out to 89.1% — medical costs growing 19% on 14% premium growth — Optum Health lost $278 million for the year, and attributable earnings fell to $12.1 billion. Q3 2026 prints 88.4%: better than last year's 89.9%, but still nearly three points worse than FY2024's full-year level. The crisis is easing, not over.

The bull version: the 150-basis-point year-over-year improvement came with DCP flat, DSO improving, operating costs falling in absolute terms, and Optum Health's value-based drag turning from a $41 million quarter into a $735 million quarter. The company raised the full-year outlook to at least $19.50 GAAP and $20.50 adjusted — and nine-month adjusted EPS already stands at $18.30, so Q4 needs just $2.20 to clear the bar. The bear version: 70 of the 150 basis points are reserve development, membership is shrinking in every government program, Optum Health bought its margin with a 10% revenue decline, and the debt-to-capital ratio crept up to 41.7% against a 40% year-end target while the company paid out $11.2 billion in buybacks and dividends year to date.

The peer table sharpens the question. Elevance reported the same week from this ledger library:

UnitedHealth runs a lower medical ratio and a wider margin than Elevance on a revenue base more than twice the size — but Elevance grew revenue while UnitedHealth shrank, and Elevance's beat needed no reserve-development asterisk. Both are pricing their way through the same cost cycle; UnitedHealth is further along on margin and further behind on membership. Which of those two lines converges will decide 2027.

Tracking a $112 Billion Insurer in Plain Text​

A health insurer's income statement is unusually honest: premiums in, medical costs out, and the difference has to cover everything else. Modeling it in Beancount forces every one of those dollars to reconcile — the transaction below is the quarter's real P&L, and it sums to zero or the ledger refuses to validate. See how we model every company for the shared conventions.

; FY2026Q3 Income Statement — quarter ended September 30, 2026
; Check: −112694 + 76982 + 13707 + 14369 + 1073 + 963 + 76 + 190 + 1224 + 4110 = 0 ✓
 
2026-09-30 * "UnitedHealth Group Incorporated" "FY2026Q3 Income Statement"
  Income:Revenue                         -112694 MUSD
  Expenses:CostOfRevenue                    76982 MUSD
  Expenses:CostOfRevenue                    13707 MUSD
  Expenses:SellingGeneralAdministrative     14369 MUSD
  Expenses:DepreciationAndAmortization       1073 MUSD
  Expenses:Interest                            963 MUSD
  Expenses:OtherNet                             76 MUSD
  Expenses:OtherNet                            190 MUSD
  Expenses:IncomeTax                         1224 MUSD
  Equity:Adjustments                         4110 MUSD

(Beancount sign convention: income posts negative as a credit, expenses positive as debits, and the Equity:Adjustments line absorbs the $4,110 million of attributable net income so the transaction nets to zero. The two CostOfRevenue postings are medical costs and cost of products sold; the two OtherNet postings are the $76 million held-for-sale loss and the $190 million of earnings attributable to noncontrolling interests.)

The balance-sheet number that tells the narrative is goodwill: $110,499 million at year-end 2025, over a third of total assets — the accumulated purchase price of every acquisition that built Optum. Against it sits medical costs payable of $39,352 million, the reserve estimate this entire quarter's story depends on:

2026-09-29 pad Liabilities:Current:MedicalClaimsPayable        Equity:Adjustments
2026-09-30 balance Liabilities:Current:MedicalClaimsPayable               -39352 MUSD

One modeling note: no 10-Q had been filed when this ledger was built, so the Q3 balance sheet comes from the earnings release's condensed presentation, which prints equity as a single $104,129 million total. That aggregate sits on Equity:UndisaggregatedParent until the annual report restores the split — the same convention the library uses for every summary-balance-sheet quarter.

The Multi-Year Arc: Revenue Up, Earnings Halved, Now Stabilizing​

Three annuals plus the new quarter tell the full arc:

(9M 2026 MCR computed as nine-month medical costs of $225,829 million over premiums of $261,595 million.)

Revenue compounded upward every year — $371.6 billion to $447.6 billion in two years — while attributable earnings nearly halved, from $22.4 billion to $12.1 billion. FY2024's damage came from the $8.3 billion South America sale loss; FY2025's came from operations, as the medical ratio blew through 89% and Optum Health lost money for the year. Nine months into 2026, the company has already earned $15.9 billion attributable — more than all of FY2025 — with an 86.4% nine-month MCR sitting between the FY2024 and FY2025 marks. Capital allocation never paused for the crisis: long-term debt roughly flat near $72 billion, share count down from 938 million diluted in FY2023 to 902 million this quarter, and $11.2 billion returned to holders in the first nine months of 2026 alone.

The Verdict: Bull vs. Bear​

Bull Case

• The MCR inflection is real and broad: −150 bp year over year with DCP flat at 47.0, operating costs down $854 million in absolute dollars, and every segment's margin expanding at once.
• Optum Health's $41 million → $735 million earnings swing shows the value-based care drag — the thing that lost $278 million in FY2025 — is being fixed by exiting bad markets, not by hoping they improve.
• Nine-month attributable earnings of $15.9 billion already exceed full-year 2025, and the raised guide (≥$19.50 GAAP) needs only ~$1.8 billion in Q4 — a bar Q3 just cleared more than twice over.
• Cash conversion is intact: $5.1 billion of quarterly operating cash flow at 1.2x net income, and $25.1 billion over nine months funding $11.2 billion of buybacks and dividends with room to spare.
• Premium per member is rising while membership falls — pricing discipline that sticks would re-rate the whole forward book, since next year's premiums are negotiated off this year's cost base.

Bear Case

• $610 million of the medical-cost beat — about 70 of the 150 basis points — is favorable reserve development, an estimate revision rather than incurred-cost improvement, and the release's own pricing language ("pricing discipline," "benefit and pricing alignment") has no demand-side corroboration anywhere in the document.
• Membership is shrinking where it matters most: 48.3 million vs 50.1 million a year ago, Medicare Advantage down 935,000 since year-end — shedding members flatters this year's ratio and shrinks next year's premium base.
• Optum Health's margin recovery cost 10% of its revenue; a care-delivery business that must shrink to earn raises the question of how much of the $110.5 billion of goodwill is still worth carrying.
• Debt-to-capital rose to 41.7% against a 40% year-end target while the company returned $11.2 billion to shareholders — deleveraging is being deferred, not delivered.
• GAAP earnings ran ahead of underlying earnings: the quarter's adjustments subtract $222 million of net divestiture and restructuring gains, so the clean number is smaller than the headline, not larger.

Our Take: This is a genuine inflection wearing a slightly too-flattering headline. Strip out the $610 million of reserve development and the MCR still improved ~80 basis points on real cost management, operating costs fell in absolute dollars while investment accelerated, and every segment expanded margins simultaneously — that breadth is what separates a one-quarter release-driven beat from a turnaround. But the turnaround is being bought with membership, and a managed-care company cannot shrink its way to growth forever. The number to watch next quarter is not the ratio but the member count: if 48.3 million stabilizes while the ratio holds below 89%, UnitedHealth is fixed. If membership keeps sliding, this quarter was triage, not recovery.